Graham Pawelec Biosketch

Graham Pawelec
Graham Pawelec

Graham Pawelec received an MA in Natural Sciences in 1978 and a PhD in Transplantation Immunology in 1982 from the University of Cambridge, UK, and the Dr. habil and Venia Legendi from the University of Tübingen, Germany, where he became Professor of Experimental Immunology in 1997. He was affiliated with the Center for Medical Research, University of Tübingen Medical School, until April 2019, and from 1st May, 2019 with the Department of Immunology (Head: Prof. H-G. Rammensee)


His research interests are centered on alterations to immunity, especially T cell-mediated immunity, in ageing, age-associated diseases and cancer in man and the influence these have on the outcome of vaccination.


He is a Visiting Professor at Nottingham Trent University, UK, and at King´s College, London, U. He is an Honorary Professor at Manchester University, UK and is on the Faculty of the Cancer Solutions Program, Health Sciences North Research Institute, Sudbury, ON, Canada. He is a member of the Scientific Advisory Board for Repair Biotechnologies, Inc, New York, USA. He is Co-Editor-in Chief of Cancer Immunology Immunotherapy, and of Immunity & Ageing, Deputy Editor of the Journal of Translational Medicine, Associate Editor of Mechanisms of Ageing & Development, and on the Editorial Boards of J. Gerontology Series A, Age, Experimental Gerontology and Biogerontology. Total citations: 26050, H-index 88 (Google Scholar), average citations per PubMed-listed article, 49.0 (as of November 2019). He has coordinated three European Union collaborative programs on immunosenescence (EUCAMBIS, ImAginE and T-CIA) and two on cancer vaccine research (EUCAPS, ESTDAB). He was an EU 5th Framework Program Expert Advisory Panel Member for Ageing and Public Health, 1997, and 7th FP Expert Consultant for the ‘Road map for the future of ageing research in Europe’, 2007 as well as the 7th FP “WhyWeAge” 2010 consulting exercise to make recommendations on the priorities for European research on ageing over the next decade. He was a member of the Sanofi-Pasteur-MSD, Sanofi-Aventis, Astellas, Pfizer and Seqirus Advisory Boards on Immunosenescence and Vaccination, and of the WHO Initiative for Vaccine Research Advisory Board on the Impact of Ageing on Vaccination.

Graham Pawelec in Google scholar and LinkedIn.